Shiba Inu Whales Surge as Shibarium Plans Privacy Push

Finance Share Share this article

Copy linkX (Twitter)LinkedInFacebookEmail

PNC Bank Rolls Out Spot Bitcoin Ac

The post Fed Decides On Interest Rates Today—Here’s What To Watch For appeared on BitcoinEthereumNews.com. Topline The Federal Reserve on Wednesday will conclude a two-day policymaking meeting and release a decision on whether to lower interest rates—following months of pressure and criticism from President Donald Trump—and potentially signal whether additional cuts are on the way. President Donald Trump has urged the central bank to “CUT INTEREST RATES, NOW, AND BIGGER” than they might plan to. Getty Images Key Facts The central bank is poised to cut interest rates by at least a quarter-point, down from the 4.25% to 4.5% range where they have been held since December to between 4% and 4.25%, as Wall Street has placed 100% odds of a rate cut, according to CME’s FedWatch, with higher odds (94%) on a quarter-point cut than a half-point (6%) reduction. Fed governors Christopher Waller and Michelle Bowman, both Trump appointees, voted in July for a quarter-point reduction to rates, and they may dissent again in favor of a large cut alongside Stephen Miran, Trump’s Council of Economic Advisers’ chair, who was sworn in at the meeting’s start on Tuesday. It’s unclear whether other policymakers, including Kansas City Fed President Jeffrey Schmid and St. Louis Fed President Alberto Musalem, will favor larger cuts or opt for no reduction. Fed Chair Jerome Powell said in his Jackson Hole, Wyoming, address last month the central bank would likely consider a looser monetary policy, noting the “shifting balance of risks” on the U.S. economy “may warrant adjusting our policy stance.” David Mericle, an economist for Goldman Sachs, wrote in a note the “key question” for the Fed’s meeting is whether policymakers signal “this is likely the first in a series of consecutive cuts” as the central bank is anticipated to “acknowledge the softening in the labor market,” though they may not “nod to an October cut.” Mericle said he…

TLDR JPMorgan initiated coverage on Vor Biopharma (NASDAQ:VOR) with an Overweight rating and $43 price target, representing over 400% upside from current levels The investment bank views telitacicept, a dual APRIL/BAFF inhibitor licensed from RemeGen, as “highly de-risked” across multiple autoimmune disease indications Vor Biopharma owns rights to telitacicept outside of China, targeting Myasthenia Gravis [...] The post Vor Biopharma (VOR) Stock Explodes 40% as JPMorgan Sees Massive Upside Ahead appeared first on Blockonomi.